The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). The data being presented represents the first study comparing miR-31-3p expression in mCRC patients treated in first line with either anti-EGFR or anti-VEGF therapy. Among the more than 5,800 abstracts submitted to ASCO, only a limited number are accepted for poster presentation, and a fraction of these are selected for the poster discussion session. This emphasizes the importance and interest in the results of this analysis of miR-31-3p in mCRC patients. IntegraGen will provide a detailed overview of the study results once presented.

Link to abstract: